SALT
LAKE CITY, Aug. 27, 2024 /PRNewswire/ -- Lipocine
Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its
proprietary technology platform to augment therapeutics through
effective oral delivery, today announced that Dr. Mahesh V. Patel, President and Chief Executive
Officer, will present and meet with investors at the H.C.
Wainwright 26th Annual Global Investment Conference being held
in-person and virtually on September 9-11,
2024.
Presentation Details
Time:
Available from 7:00 a.m. EDT
onwards
Date:
Monday, September 9, 2024
Webcast Link:
https://journey.ct.events/view/50f7964c-3a38-4f56-9dfa-454d6c66e39f
Investors can register for the conference here. Those interested
in arranging a 1x1 meeting with Lipocine should contact their H.C.
Wainwright representative.
About Lipocine
Lipocine is a biopharmaceutical company
leveraging its proprietary technology platform to augment
therapeutics through effective oral delivery to develop
differentiated products. Lipocine has drug candidates in
development as well as drug candidates for which we are exploring
partnerships. Our drug candidates represent enablement of
differentiated, patient friendly oral delivery options for
favorable benefit to risk profile which target large addressable
markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154,
oral brexanolone, for the potential treatment of postpartum
depression, LPCN 2101 for the potential treatment of epilepsy, LPCN
2203 an oral candidate targeted for the management of essential
tremor, LPCN 2401 an oral proprietary combination of anabolic
androgen receptor agonist and α-tocopherol, an antioxidant, as an
adjunct therapy to incretin mimetics, as an aid for improved body
composition in chronic weight management and LPCN 1148, a novel
androgen receptor agonist prodrug for oral administration targeted
for the management of symptoms associated with liver
cirrhosis. Lipocine is exploring partnering opportunities for
LPCN 1107, our candidate for prevention of preterm birth, LPCN
1154, for rapid relief of postpartum depression, LPCN 2401 for
chronic weight management, LPCN 1148, for the management of
decompensated cirrhosis, and LPCN 1144, our candidate for treatment
of non-cirrhotic NASH. TLANDO, a novel oral prodrug of
testosterone containing testosterone undecanoate developed by
Lipocine, is approved by the FDA for conditions associated with a
deficiency of endogenous testosterone, also known as hypogonadism,
in adult males. For more information, please visit
www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding our product development efforts, our
strategic plans for developing products, our ability
to monetize product candidates, including through entering
into partnering arrangements, our product candidates and related
clinical trials, the achievement of milestones within and
completion of clinical trials, the timing and completion of
regulatory reviews, outcomes of clinical trials of our product
candidates, and the potential uses and benefits of our product
candidates. Investors are cautioned that all such
forward-looking statements involve risks and uncertainties,
including, without limitation, the risks that we may not be
successful in developing product candidates, we may not have
sufficient capital to complete the development processes for our
product candidates, we may not be able to enter into partnerships
or other strategic relationships to monetize our non-core assets,
the FDA will not approve any of our products, risks related to our
products, expected product benefits not being realized, clinical
and regulatory expectations and plans not being realized, new
regulatory developments and requirements, risks related to the FDA
approval process including the receipt of regulatory approvals, and
our ability to utilize a streamlined approval pathway for LPCN
1154, the results and timing of clinical trials, patient acceptance
of Lipocine's products, the manufacturing and commercialization of
Lipocine's products, and other risks detailed in Lipocine's filings
with the SEC, including, without limitation, its Form 10-K and
other reports on Forms 8-K and 10-Q, all of which can be obtained
on the SEC website at www.sec.gov. Lipocine assumes no
obligation to update or revise publicly any forward-looking
statements contained in this release, except as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-hc-wainwright-26th-annual-global-investment-conference-302230689.html
SOURCE Lipocine Inc.